Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HIK.L and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HIK.L and 80,000+ other tickers.
See exactly how HIK.L's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HIK.L and 80,000+ other tickers.
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is…
London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) chairman David Lenigas joined Proactive's Stephen Gunnion to discuss the Black Star gold project and the...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8...
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of...
Cleveland and Columbus, Ohio, June 01, 2026 (GLOBE NEWSWIRE) -- COLUMBUS and CLEVELAND, Ohio - Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other state and local partners, today announced plans for a significant expansion of Hikma's manufacturing operations in Ohio, reinforcing the company's commitment to the state's growing pharmaceutical and biomanufacturing industry.
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares fell 1.45p to 1,494p, its lowest since late 2022, on news that Riad Mishlawi is stepping down as chief...